This finding also supports the opinion expressed by Groskopf et al., that PCA3 as a tissue-based overexpressed biomarker can be a promising urinary marker that can support the diagnosis and management of prostate cancer in clinical practice [49]. The gene discussed is PCA3; the disease is prostate carcinoma.